Is secukinumab a safe alternative treatment for ankylosing spondylitis with Guillain Barré syndrome after anti-TNF-α treatment? Case report and literature review

In this report, we aim to add to the existing body of evidence regarding a link between anti- tumor necrosis factor alpha (anti-TNF-α) treatment and demyelination leading to neurological disorders, specifically Guillain Barré syndrome (GBS), and treatment with an interleukin-17A (IL17A) antagonist a...

Ausführliche Beschreibung

Gespeichert in:

Bibliographische Detailangaben
Veröffentlicht in:	Clinical rheumatology 2017-05, Vol.36 (5), p.1197-1199
Hauptverfasser:	Psarelis, Savvas, Hajineocli, Andreas P. D., Hadjicosta, Eleni, Elliott, Hugh St. A., Johnson, Paul
Format:	Artikel
Sprache:	eng
Schlagworte:	Antibodies, Monoclonal - administration & dosage Case Based Review Etanercept - therapeutic use Guillain-Barre Syndrome - complications Guillain-Barre Syndrome - drug therapy Humans Immunoglobulins, Intravenous - therapeutic use Immunologic Factors - therapeutic use Immunosuppressive Agents - therapeutic use Interleukin-17 Male Medicine Medicine & Public Health Middle Aged Rheumatology Spondylitis, Ankylosing - complications Spondylitis, Ankylosing - drug therapy Tumor Necrosis Factor-alpha - antagonists & inhibitors
Online-Zugang:	Volltext
Tags:	Tag hinzufügen Keine Tags, Fügen Sie den ersten Tag hinzu!

Schreiben Sie den ersten Kommentar!